Methotrexate-induced posterior reversible encephalopathy syndrome

Journal of Clinical Pharmacy and Therapeutics

Volumn 36, Issue 4, 2011, Pages 529-536

  Aradillas, E ^a   Arora, R ^a   Gasperino, J ^b  

^a Department of Neurology ^*  (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

methotrexate; neurotoxicty; PRES

Indexed keywords

ALLOPURINOL; APREPITANT; CARBOPLATIN; CISPLATIN; CYTARABINE; ETIRACETAM; ETOPOSIDE; GABAPENTIN; GADOLINIUM; HYDROCORTISONE; IFOSFAMIDE; LIDOCAINE; MEROPENEM; METHOTREXATE; METHYLPREDNISOLONE; OMEPRAZOLE; PYRIDOXINE; RITUXIMAB; VANCOMYCIN;

ADD ON THERAPY; ADULT; ARTICLE; ARTIFICIAL VENTILATION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CASE REPORT; CLINICAL FEATURE; DIAGNOSTIC IMAGING; DIFFUSION WEIGHTED IMAGING; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAM; FEMALE; FLOW CYTOMETRY; GRAND MAL SEIZURE; HUMAN; HUMAN TISSUE; INTENSIVE CARE UNIT; LARGE CELL LYMPHOMA; LUMBAR PUNCTURE; MENTAL HEALTH; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; SIDE EFFECT; TONIC CLONIC SEIZURE; UNRESPONSIVENESS;

AGE FACTORS; ANTIMETABOLITES, ANTINEOPLASTIC; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; INJECTIONS, SPINAL; LYMPHOMA, LARGE B-CELL, DIFFUSE; METHOTREXATE; MIDDLE AGED; POSTERIOR LEUKOENCEPHALOPATHY SYNDROME;

EID: 79960094058     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2010.01207.x     Document Type: Article

References (27)

1. Bartynski WS, (2008) Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features. AJNR. American Journal of Neuroradiology, 29, 1036-1042. (Pubitemid 351954863)
2. Bartynski WS, (2008) Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema. AJNR. American Journal of Neuroradiology, 29, 1043-1049. (Pubitemid 351954864)
3. Gokce M, Dogan E, Nacitarhan S, Demirpolat G, (2006) Posterior reversible encephalopathy syndrome caused by hypertensive encephalopathy and acute uremia. Neurocritical Care, 4, 133-136. (Pubitemid 43793343)
4. Balin J, Parmar H, Kujawski L, (2008) Conventional and diffusion-weighted MRI findings of methotrexate related sub-acute neurotoxicity. Journal of the Neurological Sciences, 269, 169-171.
5. Dicuonzo F, Salvati A, Palma M, Lefons V, Lasalandra G, De Leonardis F, Santoro N, (2009) Posterior reversible encephalopathy syndrome associated with methotrexate neurotoxicity: conventional magnetic resonance and diffusion-weighted imaging findings. Journal of Child Neurology, 24, 1013-1018.
6. Inaba H, Khan RB, Laningham FH, Crews KR, Pui CH, Daw NC, (2008) Clinical and radiological characteristics of methotrexate-induced acute encephalopathy in pediatric patients with cancer. Annals of Oncology, 19, 178-184.
7. Reddick WE, Glass JO, Helton KJ, et al. (2005) Prevalence of leukoencephalopathy in children treated for acute lymphoblastic leukemia with high-dose methotrexate. AJNR. American Journal of Neuroradiology, 26, 1263-1269. (Pubitemid 43821984)
8. Renard D, Westhovens R, Vandenbussche E, Vandenberghe R, (2004) Reversible posterior leucoencephalopathy during oral treatment with methotrexate. Journal of Neurology, 251, 226-228. (Pubitemid 38221640)
9. Sandoval C, Kutscher M, Jayabose S, Tenner M, (2003) Neurotoxicity of intrathecal methotrexate: MR imaging findings. AJNR. American Journal of Neuroradiology, 24, 1887-1890. (Pubitemid 37280543)
10. Shuper A, Stark B, Kornreich L, Cohen IJ, Avrahami G, Yaniv I, (2002) Methotrexate-related neurotoxicity in the treatment of childhood acute lymphoblastic leukemia. The Israel Medical Association Journal, 4, 1050-1053.
11. Sioka C, Kyritsis AP, (2009) Central and peripheral nervous system toxicity of common chemotherapeutic agents. Cancer Chemotherapy and Pharmacology, 63, 761-767.
12. Siu A, Drachtman R, (2007) Dextromethorphan: a review of N-methyl-d-aspartate receptor antagonist in the management of pain. CNS Drug Reviews, 13, 96-106. (Pubitemid 46697843)
13. Vezmar S, Schüsseler P, Becker A, Bode U, Jaehde U, (2009) Methotrexate-associated alterations of the folate and methyl-transfer pathway in the CSF of ALL patients with and without symptoms of neurotoxicity. Pediatric and Blood Cancer, 52, 26-32.
14. Weigel R, Senn P, Weis J, Krauss JK, (2004) Severe complications after intrathecal methotrexate (MTX) for treatment of primary central nervous system lymphoma (PCNSL). Clinical Neurology and Neurosurgery, 106, 82-87. (Pubitemid 38299268)
15. Werling LL, Lauterbach EC, Calef U, (2007) Dextromethorphan as a potential neuroprotective agent with unique mechanisms of action. Neurologist, 13, 272-293. (Pubitemid 47396313)
16. Henderson RD, Rajah T, Nicol AJ, Read SJ, (2003) Posterior leukoencephalopathy following intrathecal chemotherapy with MRA-documented vasospasm. Neurology, 60, 326-328. (Pubitemid 36152032)
17. Küker W, Bader P, Herrlinger U, Heckl S, Nägele T, (2005) Transient encephalopathy after intrathekal methotrexate chemotherapy: diffusion-weighted MRI. Journal of Neuro-Oncology, 73, 47-49. (Pubitemid 40823266)
18. Linnebank M, Pels H, Kleczar N, et al. (2005) MTX-induced white matter changes are associated with polymorphisms of methionine metabolism. Neurology, 64, 912-913. (Pubitemid 40316339)
19. Marcon G, Giovagnoli AR, Mangiapane P, Erbetta A, Tagliavini F, Girotti F, (2009) Regression of chronic posterior leukoencephalopathy after stop of methotrexate treatment. Neurology Science, 30, 375-378.
20. Raghavendra S, Nair MD, Chemmanam T, Krishnamoorthy T, Radhakrishnan VV, Kuruvilla A, (2007) Disseminated necrotizing leukoencephalopathy following low-dose oral methotrexate. European Journal of Neurology, 14, 309-314. (Pubitemid 46384869)
21. Szawarski P, Chapman CS, (2005) A woman who couldn't speak: report of methotrexate neurotoxicity. Postgraduate Medical Journal, 81, 194-195. (Pubitemid 40387971)
22. Morris EB, Laningham FH, Sandlund JT, Khan RB, (2007) Posterior reversible encephalopathy syndrome in children with cancer. Pediatric and Blood Cancer, 48, 152-159. (Pubitemid 44958271)
23. Incecik F, Hergüner MO, Altunbasak S, Erbey F, Leblebisatan G, (2009) Evaluation of nine children with reversible posterior encephalopathy syndrome. Neurology India, 57, 475-478.
24. Ziereisen F, Dan B, Azzi N, Ferster A, Damry N, Christophe C, (2006) Reversible acute methotrexate leukoencephalopathy: atypical brain MR imaging features. Pediatric Radiology, 36, 205-212.
25. Vezmar S, Becker A, Bode U, Jaehde U, (2003) Biochemical and clinical aspects of methotrexate neurotoxicity. Chemotherapy, 49, 92-104. (Pubitemid 36469805)
26. Leke R, Oliveira DL, Schmidt AP, et al. (2006) Methotrexate induces seizure and decreases glutamate uptake in brain slices: prevention by ionotropic glutamate receptors antagonists and adenosine. Life Sciences, 80, 1-8. (Pubitemid 44809292)
27. Cohen IJ, (2007) Prevention of high-dose methotrexate neurotoxicity by adequate folinic acid rescue is possible even after central nervous system irradiation. Medical Hypotheses, 68, 1147-1153. (Pubitemid 46274026)